NCT00004999

Brief Summary

The purpose of this study is to look at the effectiveness of giving a new anti-HIV drug (AG1549) plus Viracept (nelfinavir) plus Combivir (a tablet containing zidovudine plus lamivudine) to HIV-infected patients who are not taking anti-HIV drugs.

Trial Health

45
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial recruitment is currently suspended
Enrollment
350

participants targeted

Target at P75+ for phase_2 hiv-infections

Geographic Reach
4 countries

53 active sites

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 1999

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

March 21, 2000

Completed
1.4 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

June 24, 2005

Status Verified

March 1, 2001

First QC Date

March 21, 2000

Last Update Submit

June 23, 2005

Conditions

Keywords

Drug Therapy, CombinationZidovudineHIV Protease InhibitorsLamivudineDisease ProgressionReverse Transcriptase InhibitorsAnti-HIV AgentsViral LoadNelfinavirCombivir

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients may be eligible if they:
  • Are HIV-positive.
  • Are at least 18 years old.
  • Have a CD4 cell count of more than 50 cells/mm3.
  • Have an HIV level of more than 5000 copies/ml.

You may not qualify if:

  • Patients will not be eligible if they:
  • Have ever taken any of the following anti-HIV drugs: nonnucleoside reverse transcriptase inhibitors (NNRTIs), AG1549, Viracept, zidovudine, lamivudine, or Combivir. Other anti-HIV drugs are allowed only if taken for no more than 30 days with the last dose taken more than 6 months prior to study entry.
  • Have taken an experimental drug within 28 days of study entry.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (53)

Arizona Clinical Research Ctr Inc

Tucson, Arizona, 85712, United States

Location

Univ of Southern California

Los Angeles, California, 90033, United States

Location

Highland Gen Hosp / San Francisco Gen Hosp

Oakland, California, 946021018, United States

Location

ViRx Inc

Palm Springs, California, 92262, United States

Location

Research & Treatment at the California Pacific Med Ctr

San Francisco, California, 94114, United States

Location

Harbor - UCLA Med Ctr

Torrance, California, 90502, United States

Location

IDC Research Initiative

Altamonte Springs, Florida, 32701, United States

Location

Bach and Godofsky

Bradenton, Florida, 34205, United States

Location

Community Health Care

Fort Lauderdale, Florida, 33306, United States

Location

Univ of Florida

Jacksonville, Florida, 32209, United States

Location

Univ of Miami School of Medicine

Miami, Florida, 33136, United States

Location

South Shore Hosp

Miami, Florida, 33139, United States

Location

Specialty Med Care Ctrs of South Florida Inc

Miami, Florida, 33142, United States

Location

Orange County Health Dept

Orlando, Florida, 32805, United States

Location

Larry Bush

Palm Springs, Florida, 33461, United States

Location

Infectious Diseases Associates

Sarasota, Florida, 34239, United States

Location

Infectious Disease Research Institute

Tampa, Florida, 33614, United States

Location

Treasure Coast Infectious Disease Consultants

Vero Beach, Florida, 32960, United States

Location

Polk County Health Dept

Winter Haven, Florida, 33881, United States

Location

Sky Blue

Boise, Idaho, 83704, United States

Location

Northwestern Univ Med Ctr

Chicago, Illinois, 60611, United States

Location

The CORE Ctr

Chicago, Illinois, 60612, United States

Location

Indiana Univ Infectious Disease Research Clinic

Indianapolis, Indiana, 46202, United States

Location

Univ of Iowa

Iowa City, Iowa, 52242, United States

Location

Univ of Kansas School of Medicine

Wichita, Kansas, 67214, United States

Location

University of Louisville / ID Division

Louisville, Kentucky, 40202, United States

Location

HIV Outpatient Clinics / LA State Univ Med Ctr

New Orleans, Louisiana, 70112, United States

Location

Fenway Community Health Ctr

Boston, Massachusetts, 02115, United States

Location

Hawthorne Med Associates / PAACA

New Bedford, Massachusetts, 02745, United States

Location

Kansas City AIDS Research Consortium

Kansas City, Missouri, 64111, United States

Location

Univ of Nebraska Medical Ctr

Omaha, Nebraska, 681985400, United States

Location

Paul Alessi

Cherry Hill, New Jersey, 08034, United States

Location

VAMC New Jersey Healthcare System

East Orange, New Jersey, 07018, United States

Location

St Mary's Hosp Family Treatment Ctr

Hoboken, New Jersey, 07030, United States

Location

Univ of Med & Dentistry of New Jersey

Newark, New Jersey, 07103, United States

Location

Bentley-Salick Medical Practice PC

New York, New York, 10003, United States

Location

Univ of Rochester Med Ctr

Rochester, New York, 14642, United States

Location

Univ of Cincinnati / Holmes Hosp

Cincinnati, Ohio, 452670405, United States

Location

Med Univ of South Carolina

Charleston, South Carolina, 29425, United States

Location

Julio Arroyo

West Columbia, South Carolina, 29169, United States

Location

Southwest Infectious Diseases Associates

Dallas, Texas, 75246, United States

Location

Univ TX Galveston Med Branch

Galveston, Texas, 77555, United States

Location

Joseph C Gathe

Houston, Texas, 77004, United States

Location

Thomas Street Clinic

Houston, Texas, 77009, United States

Location

Hampton Roads Med Specialists

Hampton, Virginia, 23666, United States

Location

Wisconsin AIDS Research Consortium

Milwaukee, Wisconsin, 53203, United States

Location

Canadian HIV Trials Network

Vancouver, British Columbia, Canada

Location

QEII Health Science Centre

Halifax, Nova Scotia, Canada

Location

Sunnybrook Health Science Centre

Toronto, Ontario, Canada

Location

Montreal Chest Institute

Montreal, Quebec, Canada

Location

Immunity Care and Research Inc

Santo Domingo, Dominican Republic

Location

Univ of Puerto Rico School of Med

Rio Piedras, 00935, Puerto Rico

Location

Clinical Research Puerto Rico Inc

San Juan, 009091711, Puerto Rico

Location

MeSH Terms

Conditions

HIV InfectionsDisease Progression

Interventions

lamivudine, zidovudine drug combinationcapravirineNelfinavir

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

IsoquinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 2
Masking
DOUBLE
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

March 21, 2000

First Posted

August 31, 2001

Study Start

August 1, 1999

Last Updated

June 24, 2005

Record last verified: 2001-03

Locations